Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173

1.

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.

Blute ML Jr, Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W, Jarrard DF.

PLoS One. 2017 Feb 24;12(2):e0172048. doi: 10.1371/journal.pone.0172048. eCollection 2017 Feb 24.

2.

A Role for the Hedgehog Effector Gli1 in Mediating Stent-induced Ureteral Smooth Muscle Dysfunction and Aperistalsis.

Janssen C, Buttyan R, Seow CY, J├Ąger W, Solomon D, Fazli L, Chew BH, Lange D.

Urology. 2017 Feb 8. pii: S0090-4295(17)30110-3. doi: 10.1016/j.urology.2017.01.029. [Epub ahead of print]

PMID:
28188758
3.

MR measurement of luminal water in prostate gland: Quantitative correlation between MRI and histology.

Sabouri S, Fazli L, Chang SD, Savdie R, Jones EC, Goldenberg SL, Black PC, Kozlowski P.

J Magn Reson Imaging. 2017 Jan 27. doi: 10.1002/jmri.25624. [Epub ahead of print]

PMID:
28130866
4.

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.

Tse BW, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG.

Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.482. [Epub ahead of print]

PMID:
28092670
5.

Effect of contrast media on urinary cytopathology specimens.

Frees S, Bidnur S, Metcalfe M, Raven P, Chavez-Munoz C, Moskalev I, Fazli L, So A.

Can Urol Assoc J. 2016 Aug;10(7-8):228-233.

6.

MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.

Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD.

PLoS One. 2016 Nov 15;11(11):e0165236. doi: 10.1371/journal.pone.0165236. eCollection 2016 Nov 15.

7.

UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling.

Li H, Xie N, Chen R, Verreault M, Fazli L, Gleave ME, Barbier O, Dong X.

Cancer Res. 2016 Nov 15;76(22):6701-6711. doi: 10.1158/0008-5472.CAN-16-1518. Epub 2016 Sep 22.

PMID:
27659047
8.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

PMID:
27784708
9.

Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.

Dejima T, Imada K, Takeuchi A, Shiota M, Leong J, Tombe T, Tam K, Fazli L, Naito S, Gleave ME, Ong CJ.

Prostate. 2017 Feb;77(3):309-320. doi: 10.1002/pros.23269. Epub 2016 Oct 24.

PMID:
27775154
10.

Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.

McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Am J Surg Pathol. 2016 Nov;40(11):1439-1456.

PMID:
27635949
11.

c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.

Maina PK, Shao P, Liu Q, Fazli L, Tyler S, Nasir M, Dong X, Qi HH.

Oncotarget. 2016 Nov 15;7(46):75585-75602. doi: 10.18632/oncotarget.12310.

12.

Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33.

Saranchova I, Han J, Huang H, Fenninger F, Choi KB, Munro L, Pfeifer C, Welch I, Wyatt AW, Fazli L, Gleave ME, Jefferies WA.

Sci Rep. 2016 Sep 13;6:30555. doi: 10.1038/srep30555.

13.

PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Eur Urol Focus. 2016 Jun;2(2):180-188.

PMID:
27617307
14.

Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting.

Clausen TM, Pereira MA, Oo HZ, Resende M, Gustavson T, Mao Y, Sugiura N, Liew J, Fazli L, Theander TG, Daugaard M, Salanti A.

Sens Biosensing Res. 2016 Jul;9:23-30.

15.

Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.

Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L.

Prostate. 2016 Nov;76(15):1409-19. doi: 10.1002/pros.23225. Epub 2016 Jun 21.

PMID:
27325561
16.

Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.

Annala M, Nappi L, Azad AA, Mo F, Fazli L, Chi KN, Wyatt AW.

Clin Genitourin Cancer. 2017 Feb;15(1):e145-e150. doi: 10.1016/j.clgc.2016.05.019. Epub 2016 May 27. No abstract available.

PMID:
27324055
17.

Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55].

Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.

Eur Urol. 2016 Jul;70(1):e27-e28. doi: 10.1016/j.eururo.2016.03.014. Epub 2016 Mar 31. No abstract available.

PMID:
27302299
18.

Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.

Al Nakouzi N, Wang CK, Beraldi E, Jager W, Ettinger S, Fazli L, Nappi L, Bishop J, Zhang F, Chauchereau A, Loriot Y, Gleave M.

EMBO Mol Med. 2016 Jul 1;8(7):761-78. doi: 10.15252/emmm.201506059. Print 2016 Jul.

19.

Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.

Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA.

Mod Pathol. 2016 Aug;29(8):904-14. doi: 10.1038/modpathol.2016.88. Epub 2016 May 13.

20.

Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70. doi: 10.1038/pcan.2016.12. Epub 2016 May 3.

PMID:
27136741

Supplemental Content

Support Center